Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: To quantify the economic burden of early-stage non-small-cell lung cancer (NSCLC) among patients with and without adjuvant therapy. Methods: All-cause and NSCLC-related healthcare resource utilization and medical costs were assessed among patients with resected stage IB–IIIA NSCLC in the SEER–Medicare database (1 January 2011–31 December 2019), from NSCLC diagnosis to death, end of continuous enrollment, or end of data availability (whichever occurred first). Results: Patients receiving adjuvant therapy had the lowest mean NSCLC-related medical costs (adjuvant [n = 1776]: $3738; neoadjuvant [n = 56]: $5793; both [n = 47]: $4818; surgery alone [n = 3478]: $4892, per-person-per-month), driven by lower NSCLC-related hospitalization rates. Conclusion: Post-surgical management of early-stage NSCLC was associated with high economic burden. Adjuvant therapy was associated with numerically lower medical costs over surgical resection alone.
Tweetable abstract
In patients with stage IB–IIIA NSCLC in the SEER–Medicare database who underwent surgical resection, adjuvant therapy was associated with lower medical costs over surgical resection alone.
Plain language summary
What is the article about?
Non-small-cell lung cancer (NSCLC) accounts for ∼84% of cases of lung cancer, which is the third-most commonly diagnosed cancer and the leading cause of cancer-related mortality in USA. A large proportion of patients with resected early-stage NSCLC experience recurrence following surgical resection, and treatment guidelines recommend adjuvant therapy to reduce the risk of recurrence. However, there have been few studies to date that quantified the healthcare resource utilization (HRU) and medical cost among patients with and without adjuvant therapy. To this end, the present study described HRU and medical costs in patients with stage IB–IIIA NSCLC in the SEER–Medicare database who underwent surgical resection, and examined the economic outcomes stratified by receipt of adjuvant therapy.
What were the results?
We found that patients receiving adjuvant therapy had the lowest mean NSCLC-related medical costs (adjuvant [n = 1776]: $3738; neoadjuvant [n = 56]: $5793; both [n = 47]: $4818; surgery alone [n = 3478]: $4892, per-person-per-month), driven by lower NSCLC-related hospitalization rates.
What do the results mean?
These results suggest that post-surgical management of early-stage NSCLC was associated with high economic burden. Adjuvant therapy was associated with lower medical costs over surgical resection alone.
Supplementary Material
File (supplementary materials.docx)
- Download
- 59.94 KB
References
Papers of special note have been highlighted as: • of interest
1.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J. Clin. 72(1), 7–33 (2022).
2.
National Cancer Institute. Seer cancer statistics review, 1975–2016. https://seer.cancer.gov/archive/csr/1975_2016/results_merged/sect_15_lung_bronchus.pdf
3.
Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of incidence, prevalence, survival, and initial treatment in patients with non–small cell lung cancer in the US. JAMA Oncol. 7(12), 1824–1832 (2021).
• This cross-sectional epidemiological analysis shows that the overall prevalence of non-small-cell lung cancer (NSCLC) in the US is substantial and increased from 2010 to 2016.
4.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann. Surg. Oncol. 17(6), 1471–1474 (2010).
5.
Flores R, Patel P, Alpert N, Pyenson B, Taioli E. Association of stage shift and population mortality among patients with non-small cell lung cancer. JAMA Netw. Open 4(12), e2137508 (2021).
6.
Hall H, Tocock A, Burdett S et al. Association between time-to-treatment and outcomes in non-small-cell lung cancer: a systematic review. Thorax 77(8), 762–768 (2022).
7.
Park J, Look KA. Health care expenditure burden of cancer care in the United States. INQUIRY: The Journal of Health Care Organization, Provision, and Financing 56, 0046958019880696 (2019).
8.
Sheehan DF, Criss SD, Chen Y et al. Lung cancer costs by treatment strategy and phase of care among patients enrolled in medicare. Cancer Med. 8(1), 94–103 (2019).
9.
Yabroff KR, Mariotto A, Tangka F et al. Annual report to the nation on the status of cancer, part 2: patient economic burden associated with cancer care. J. Natl Cancer Inst. 113(12), 1670–1682 (2021).
10.
Deboever N, Mitchell KG, Feldman HA, Cascone T, Sepesi B. Current surgical indications for non-small-cell lung cancer. Cancers 14(5), 1263 (2022).
11.
Heineman DJ, Daniels JM, Schreurs WH. Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy. Ther. Adv. Med. Oncol. 9(9), 599–609 (2017).
12.
Lu T, Yang X, Huang Y et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag. Res. 11, 943 (2019).
13.
Cai B, Fulcher N, Boyd M, Spira A. Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non-small-cell lung cancer treated with adjuvant therapies in a community oncology setting: a real-world retrospective observational study. Thorac. Cancer 12(14), 2055–2064 (2021).
14.
Fedor D, Johnson WR, Singhal S. Local recurrence following lung cancer surgery: incidence, risk factors, and outcomes. Surg. Oncol. 22(3), 156–161 (2013).
• This literature review highlights the high risk of recurrence following lung cancer surgery that warrants further research.
15.
Takenaka T, Yano T, Yamazaki K et al. Survival after recurrence following surgical resected non-small-cell lung cancer: a multicenter, prospective cohort study. JTCVS Open 10, 370–381 (2022).
16.
National Cancer Institute. non-small-cell lung cancer treatment (pdq®)–health professional version. https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq#_470
17.
Indini A, Rijavec E, Bareggi C, Grossi F. Novel treatment strategies for early-stage lung cancer: the oncologist's perspective. J. Thorac. Dis. 12(6), 3390 (2020).
18.
Salazar MC, Rosen JE, Wang Z et al. Association of delayed adjuvant chemotherapy with survival after lung cancer surgery. JAMA Oncol. 3(5), 610–619 (2017).
• This study finds that adjuvant therapy is associated with better survival than surgery alone in patients with completely resected NSCLC even when therapy is initiated later in the post-operative period.
19.
Buck PO, Saverno KR, Miller PJ, Arondekar B, Walker MS. Treatment patterns and health resource utilization among patients diagnosed with early stage resected non–small cell lung cancer at us community oncology practices. Clin. Lung Cancer 16(6), 486–495 (2015).
20.
Wu Y-L, Tsuboi M, He J et al. Osimertinib in resected egfr-mutated non–small-cell lung cancer. NEJM 383(18), 1711–1723 (2020).
• This study shows that osimertinib is associated with longer disease-free survival than placebo among patients with resected EGFRm stage II to IIIA NSCLC.
21.
Kris MG, Gaspar LE, Chaft JE et al. Adjuvant systemic therapy and adjuvant radiation therapy for Stage I to IIIA completely resected non-small-cell lung cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. J. Clin. Oncol. 35(25), 2960–2974 (2017).
22.
Pignon J-P, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 26(21), 3552–3559 (2008).
23.
Kim CS, Jeter MD. Radiation therapy for early stage non-small-cell lung cancer. In: Statpearls [internet]. StatPearls Publishing, FL, USA (2021).
24.
Le Pechoux C, Pourel N, Barlesi F et al. LBA3_PR An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small-cell lung cancer (NSCLC) and mediastinal N2 involvement: primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683. Ann. Oncol. 31, S1178 (2020).
25.
de Scordilli M, Michelotti A, Bertoli E, De Carlo E, Del Conte A, Bearz A. Targeted therapy and immunotherapy in early-stage non-small-cell lung cancer: current evidence and ongoing trials. Int. J. Mol. Sci. 23(13), 7222 (2022).
26.
Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. NEJM 352(8), 786–792 (2005).
27.
Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to egfr inhibitors. Sci. Transl. Med. 3(75), 75ra26 (2011).
28.
Soria J-C, Ohe Y, Vansteenkiste J et al. Osimertinib in untreated egfr-mutated advanced non-small-cell lung cancer. NEJM 378(2), 113–125 (2018).
29.
Jänne PA, Yang JC-H, Kim D-W et al. AZD9291 in EGFR inhibitor–resistant non-small-cell lung cancer. NEJM 372(18), 1689–1699 (2015).
30.
Mok T, Ahn M-J, Han J-Y et al. CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: data from a randomized phase III trial (AURA3). J. Clin. Oncol. 35(Suppl. 15), 9005 (2017).
31.
Herbst RS, Wu Y-L, John T et al. Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non–small-cell lung cancer: updated results from the phase III randomized ADAURA trial. J. Clin. Oncol. (2023).
• This study demonstrates that the prolonged disease-free survival benefit of adjuvant osimertinib persists in an updated exploratory analysis of the ADAURA trial.
32.
Felip E, Altorki N, Zhou C et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (impower010): a randomised, multicentre, open-label, Phase 3 trial. Lancet 398(10308), 1344–1357 (2021).
• This study shows longer disease-free survival with adjuvant atezolizumab versus best supportive care after chemotherapy in patients with resected stage II-IIIA NSCLC.
33.
O'Brien M, Paz-Ares L, Marreaud S et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (pearls/keynote-091): an interim analysis of a randomised, triple-blind, Phase 3 trial. Lancet Oncol. 23(10), 1274–1286 (2022).
34.
Vergnenègre A, Carrato A, Thomas M, Jernigan C, Medina J, Cruciani G. Real-world healthcare resource utilization in a european non-small-cell lung cancer population: the epiclin-lung study. Curr. Med. Res. Opin. 30(3), 463–470 (2014).
35.
van der Linden N, Bongers ML, Coupé VM et al. Costs of non-small-cell lung cancer in the Netherlands. Lung Cancer 91, 79–88 (2016).
36.
Shah S, Blanchette CM, Coyle JC, Kowalkowski M, Arthur ST, Howden R. Healthcare utilization and costs associated with copd among SEER-Medicare beneficiaries with NSCLC. J. Med. Econ. 21(9), 861–868 (2018).
37.
Mahar AL, Coburn NG, Johnson AP. A population-based study of the resource utilization and costs of managing resectable non-small-cell lung cancer. Lung Cancer 86(2), 281–287 (2014).
38.
Bertranou E, Bodnar C, Dansk V, Greystoke A, Large S, Dyer M. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small-cell lung cancer. J. Med. Econ. 21(2), 113–121 (2018).
39.
Andreas S, Chouaid C, Danson S et al. Economic burden of resected (Stage IB-IIIA) non-small-cell lung cancer in france, germany and the united kingdom: a retrospective observational study (lucabis). Lung Cancer 124, 298–309 (2018).
40.
National Cancer Institute. Surveillance, epidemiology, and end results program. Overview of the SEER program. https://seer.cancer.gov/about/overview.html
41.
Hess LM, Cui ZL, Wu Y, Fang Y, Gaynor PJ, Oton AB. Current and projected patient and insurer costs for the care of patients with non-small-cell lung cancer in the United States through 2040. J. Med. Econ. 20(8), 850–862 (2017).
42.
Kutikova L, Bowman L, Chang S, Long SR, Obasaju C, Crown WH. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer 50(2), 143–154 (2005).
43.
Hillner BE, McDonald MK, Desch CE et al. Costs of care associated with non-small-cell lung cancer in a commercially insured cohort. J. Clin. Oncol. 16(4), 1420–1424 (1998).
44.
Rosenthal MA, Webster PJ, Stuart-Harris RC, Langlands AO, Boyages J, Gebski VJ. The cost of treating small cell lung cancer. Med. J. Aust. 156(9), 605–611 (1992).
45.
National Comprehensive Cancer Network. non-small-cell lung cancer, version 5.2022 (2022). https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
46.
Buck PO, Saverno KR, Miller PJ, Arondekar B, Walker MS. Treatment patterns and health resource utilization among patients diagnosed with early stage resected non-small-cell lung cancer at us community oncology practices. Clin. Lung Cancer 16(6), 486–495 (2015).
• This study reveals that only half of the patients with stage IB-IIIA NSCLC who undergo surgical resection receive adjuvant therapy.
47.
Lim JU. Update on adjuvant treatment in resectable non-small-cell lung cancer and potential biomarkers predicting postoperative relapse. Tuberc. Respir. Dis. (Seoul) 86(1), 14 (2023).
48.
Lim JU, Yeo CD. Update on adjuvant therapy in completely resected NSCLC patients. Thorac. Cancer 13(3), 277–283 (2022).
49.
Chouaid C, Danson S, Andreas S et al. Adjuvant treatment patterns and outcomes in patients with Stage IB-IIIA non-small-cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. Lung Cancer 124, 310–316 (2018).
50.
Goldstraw P, Chansky K, Crowley J et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J. Thorac. Dis. 11(1), 39–51 (2016).
51.
Desage A-L, Bouleftour W, Tiffet O, Fournel P, Tissot C. Use of adjuvant chemotherapy in resected non-small-cell lung cancer in real-life practice: a systematic review of literature. Transl. Cancer Res. 10(12), 4643 (2021).
52.
Szeto CH, Shalata W, Yakobson A, Agbarya A. Neoadjuvant and adjuvant immunotherapy in early-stage non-small-cell lung cancer, past, present, and future. J. Clin. Med. 10(23), 5614 (2021).
53.
Chen R-L, Sun L-L, Cao Y et al. Adjuvant EGFR-TKIs for patients with resected EGFR-mutant non-small-cell lung cancer: a meta-analysis of 1,283 patients. Front. Oncol. 11, 629394 (2021).
54.
Lin C, Hu F, Chu H et al. The role of EGFR-TKIs as adjuvant therapy in EGFR mutation-positive early-stage NSCLC: a meta-analysis. Thorac. Cancer 12(7), 1084–1095 (2021).
55.
Zhao P, Zhen H, Zhao H, Zhao L, Cao B. Efficacy and safety of adjuvant egfr-tkis for resected non-small-cell lung cancer: a systematic review and meta-analysis based on randomized control trials. BMC Cancer 22(1), 1–15 (2022).
56.
Chen T, Zhou F, Jiang W et al. Age at diagnosis is a heterogeneous factor for non-small-cell lung cancer patients. J. Thorac. Dis. 11(6), 2251 (2019).
Information & Authors
Information
Published In
Copyright
© 2023 AstraZeneca Ltd. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 22 June 2023
Accepted: 11 August 2023
Published online: 1 September 2023
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs. (2023) Journal of Comparative Effectiveness Research. DOI: 10.57264/cer-2023-0107
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Xin Xie, Qian Chen, Cui Guo, Jinhao Zeng, Qingying He, Artemisinin and its derivatives: all-rounders that may prevent the progression from lung injury to lung cancer, Frontiers in Pharmacology, 10.3389/fphar.2025.1602581, 16, (2025).
- Simona-Maria Roșu, Denisa Maria Mitroi, Oana Maria Catană, Viorel Biciușcă, Sorina Ionelia Stan, Beatrice Mahler, Oana-Andreea Parliteanu, Adina Andreea Mirea, Mara Amalia Bălteanu, Flexible Bronchoscopy and Non-Small-Cell Lung Cancer Staging: A Narrative Review of Modern Techniques for Optimized Clinical Decision-Making, Journal of Clinical Medicine, 10.3390/jcm14165773, 14, 16, (5773), (2025).
- Charlotte Nilsen, Gudmund Ågotnes, The doxa of smoking and implications for lung cancer patients: from natural and glamorous to self-inflicted and impure, Praxeologi – et kritisk refleksivt blikk på sosiale praktikker, 10.15845/praxeologi.v7.4534, 7, (e453), (2025).
- Bryan A. Chan, Danny R. Youlden, Tracey Guan, Margot Lehman, Morgan Windsor, Alison Bolton, Nathan Dunn, Danica Cossio, Shoni Philpot, Jasotha Sanmugarajah, Setting the Benchmark: Patterns of Care and Outcomes for Early‐stage Non‐small Cell Lung Cancer in Queensland, Australia, 2011–2017, Asia-Pacific Journal of Clinical Oncology, 10.1111/ajco.14177, 21, 6, (597-606), (2025).
- Daniela Paredes-Fernández, Rony Lenz-Alcayaga, Francisco Orlandi-Jorquera, Budget impact analysis of neoadjuvant nivolumab for non-small cell lung cancer in the Chilean public healthcare system: An exploratory economic assessment, Clinical and Translational Oncology, 10.1007/s12094-025-03872-7, 27, 8, (3375-3385), (2025).
- Adam Haysom‐McDowell, Keshav Raj Paudel, Stewart Yeung, Sofia Kokkinis, Tammam El Sherkawi, Dinesh Kumar Chellappan, Jon Adams, Kamal Dua, Gabriele De Rubis, Recent trends and therapeutic potential of phytoceutical‐based nanoparticle delivery systems in mitigating non‐small cell lung cancer, Molecular Oncology, 10.1002/1878-0261.13764, 19, 1, (15-36), (2024).
- Freiser Eceomo Cruz Mosquera, Saray Rios Murillo, Anisbed Naranjo Rojas, Claudia Lorena Perlaza, Diana Castro Osorio, Yamil Liscano, Effect of Exercise and Pulmonary Rehabilitation in Pre- and Post-Surgical Patients with Lung Cancer: Systematic Review and Meta-Analysis, Medicina, 10.3390/medicina60111725, 60, 11, (1725), (2024).